TTED STATES PATENT AND TRADEMARK OFFICE

J 19-03

ICATION OF

In re PATENT APPLICATION OF

Mitchell E. Reff et al.

Group Art Unit: 1644

Application No. 09/019,441

Examiner: M. Jamroz

Filed: February 5, 1998

Title: GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE

THEREOF AS THERAPEUTICS

RECEIVED

MAR 0 3 2003

TECH CENTER 1600/2900

REPLY AND AMENDMENT

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

This reply is responsive to the Final Office Action dated October 22, 2002. Kindly enter the following amendments and remarks prior to further examination:

IN THE SPECIFICATION:

Please amend the first paragraph on page 1 to read as follows:

This application is a continuation-in-part of U.S. Application No. 08/803,085, filed February 20, 1997, now U.S. Patent No. 6,011,138, issued January 4, 2000.

IN THE CLAIMS:

Please amend claims 45-47, 49, and 54-60, and add new claims 61-70, as shown below:

- 45. A composition containing an anti-human CD23 antibody (Amended) according to claim 42 and a pharmaceutically acceptable carrier.
- A composition containing an anti-human CD23 antibody 46. according to claim 43 and a pharmaceutically acceptable carrier.